Keryx Biopharmaceuticals, Inc. (KERX) Tops Q2 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. META
3. ANT
4. SPY
5. FFAI
6. FFR
7. AZN
8. FICO
9. GMAB
10. CART

Go back to Keryx Biopharmaceuticals, Inc. (KERX) Tops Q2 EPS by 1c

Roth Maintains Keryx (KERX) at 'Buy' Following Q2 Results; Long-Term Study Data Still Looks Good

August 7, 2014 12:05 PM EDT

Roth Capital maintains Keryx Biopharmaceuticals (Nasdaq: KERX) at Buy with a target price of $30 following Q2 results.

Analyst Joseph Pantginis noted that Keryx posted Q2 loss of $0.24 per share, versus the firm's loss estimate of $0.19 per share. The analyst commented, We believe the company's commercialization ramp up indicates KERX's strong confidence in a potential U.S. approval for Zerenex. The company has stated plans to launch the product within 12... More